Overview

Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions

Status:
NOT_YET_RECRUITING

Trial end date:
2024-11-07

Target enrollment:

Participant gender:

Summary

The bioequivalence of Dabigatran Etexilate Capsules 150 mg to Boehringer Ingelheim's Pradaxa® will be assessed by a statistical comparison of various pharmacokinetic parameters derived from the plasma concentration-time curves of free dabigatran and total dabigatran.

Phase:

PHASE1

Details

Lead Sponsor:

International Bio service

Treatments:

Dabigatran